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The most common cause of pulmonary hypertension is left 
sided heart disease resulting in venous pulmonary hypertension. 
Echocardiography allows for assessment of left ventricular 
systolic and diastolic dysfunction as well as left-sided valvular 
disease and congenital heart disease.[1] Primary degenerative 
mitral valve regurgitation is a frequent and serious valvular heart 
disease that may progressively and insidiously lead to pulmonary 
hypertension.[2,3] Degenerative disease is the most common form 
of organic mitral valve disease in the United States (with an 
estimated incidence of 2–3%),[4] and in other developed countries. 
Degenerative valvular heart diseases are the most common 
echocardiographic abnormalities in the elderly population in 
South-East Nigeria.[5] Normal mean pulmonary artery (PA) 
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Abstract
Background: Pulmonary hypertension is a common complication of degenerative mitral valve 
disease, and contributes significantly to both morbidity and mortality. The use of medications 
for reduction of pulmonary pressure in patients is not a common practice by most physicians 
in this part of the world because of the absence of data on pulmonary hypertension. Aim: The 
authors set out to find the prevalence of pulmonary hypertension in patients with degenerative 
mitral valve disease and to determine if there are gender differences in affectation. This will 
form a basis for future research on the management of pulmonary hypertension in sub‑Saharan 
Africa. Subjects and Methods: The echocardiographic records of 1390 patients carried out 
over a period of 4 years were retrospectively reviewed. The examinations were done with 
a Logic 500 MD echocardiographic machine. Tricuspid valve regurgitation velocity above 
250 cm/s defined pulmonary hypertension. Data obtained included presence of degenerative 
mitral valve disease, pulmonary hypertension, age, and gender. Results: A total of 1390 
echocardiogram reports done at Conquest Medical Imaging, Enugu, from July 2009 to August 
2013 were retrospectively reviewed. Degenerative mitral valve disease was noted in 18.7% 
of the patients, (259/1390) made up of 149 males and 110 females with a mean age of 68.3 
(14.4) years. Pulmonary hypertension was present in 30% of the patients (78/259) and affected 
males more than females. Conclusion: Pulmonary hypertension is common in patients with 
degenerative mitral valve disease in Enugu, and affects males more than females.
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hypertension is defined as mean PA pressure exceeding 25 mmHg 
at rest as measured by right heart catheterization.[6]
Echocardiographic estimates of PA pressures are almost always 
made based on a measure of the tricuspid regurgitation jet 
velocity, which appears to be measurable in the overwhelming 
majority of, though not all, patients.[7] A number of studies have 
examined the sensitivity of echocardiography for the diagnosis of 
pulmonary hypertension, using cardiac catheterization as a gold 
standard. These studies have found sensitivities ranging from 
79% to 100%.[8,9] Furthermore, most studies have found excellent 
correlations between PA pressure estimated by echocardiography 
and that measured by catheterization.[10] The most commonly 
used modality to estimate PA systolic pressure (PASP) is Doppler 
echocardiography. PASP can be determined by measuring the 
peak systolic pressure gradient from the right ventricle to the 
right atrium.[11] This is calculated using the modified Bernoulli 
equation: 4V2, where v is the maximum velocity of the tricuspid 
valve regurgitant jet, measured by continuous wave Doppler, 
added to the estimated right atrial pressure.[10]
There is a dearth of data on all aspects of pulmonary 
hypertension in sub-Saharan Africa, and the authors set out 
to find the frequency and burden of pulmonary hypertension 
in patients with degenerative mitral valve disease diagnosed 
by transthoracic echocardiography.
Subjects and Methods
Conquest Medical Imaging is a private medical diagnostic center 
in Enugu, South-East Nigeria. The center offers radiologic and 
ultrasonographic diagnostic services. The echocardiographic 
records of 1390 patients done over a 4-year period (July 2009–
August 2013) were retrospectively reviewed. The examinations 
were done with a Logic 500 MD echocardiographic machine 
made by General Electric (GE: New York). The machine has 
the capability for two-dimensional, M-mode, and Doppler 
examinations, and is equipped with an inbuilt printer. The studies 
were done on outpatients who came to the private facility. Our 
institutional ethical committee approved the study patients 
with a clinical diagnosis of sleep apnea, chronic obstructive 
airway disease or obesity on their request form were excluded 
from the study. Hypertensive patients who were referred for 
echocardiographic examination were included in the study. 
Patients with rheumatic heart disease, congenital heart diseases 
were also excluded. All other patients with degenerative 
mitral valve disease were included in the study. Tricuspid 
valve regurgitant velocity above 250 cm/s defined pulmonary 
hypertension.[11] Data obtained included presence of degenerative 
mitral valve disease, pulmonary hypertension, age, and gender.
Data were presented as means (standard deviation) for continuous 
variables and as proportions for categorical variables. Comparison 
of continuous variables between groups (male and female) was 
made with independent Student’s t-test. For discrete variables, 
distribution between groups was compared with Chi-square test 
and Fisher’s exact test as appropriate (where an expected cell 
is <5). Age-related differences in the prevalence of pulmonary 
hypertension among patients with mitral valve disease were 
evaluated using Chi-square for trend. All statistical analyses were 
carried out using the Statistical Packages for Social Sciences (SPSS 
Inc., Chicago Illinois, USA) software version 16.0. Statistical tests 
with two-tailed P < 0.05 were considered statistically significant.
Results
There were 1390 echocardiogram reports over the study 
period. Degenerative mitral valve disease was noted in 
259 patients (18.7%), made up of 149 males and 110 females 
with a mean age of 68.3 (14.4) years. The mean age of the 
females was 71.7 (12.3) years while the mean age of the males 
was 68.4 (10.2) years. Pulmonary hypertension was present in 
78 patients, representing 30% of the study population, and made 
up of 47 males and 31 females. Pulmonary hypertension was 
noted in about 31.5% (47/149) of all the males with degenerative 
mitral valve disease while about 28.2% (31/110) of the 
females with degenerative mitral valve disease had pulmonary 
hypertension. Severe pulmonary hypertension (PA pressure 
of >50 mmHg),[10] was noted in most patients with Grade 4 mitral 
regurgitation (MR) on color flow mapping. The differences were 
statistically significant (χ2 = 15.844; df = 1, P = 0.001 [McNemar 
test]). The prevalence of pulmonary hypertension in patients with 
mitral valve disease increased progressively with advancing age 
of the patients, (χ2 for trend = 4.1000; P = 0.043). The mean 
age of the males with pulmonary hypertension was 70.4 (11.1) 
years while the mean age of the females was 66.9 years, and the 
differences were statistically significant (P = 0.038).
Discussion
Our study documented a frequency of 30% for pulmonary 
hypertension among the study population. This is definitely 
higher than the frequency of 15% reported by Magne et al.[12] 
The higher frequency in our study may be due to the relatively 
older population in our study sample. Over 50% of subjects in 
our study population aged 85 years and above had pulmonary 
hypertension [Table 1]. Resting systolic pulmonary pressure 
Table 1 : Age and gender distribution of pulmonary 
















50‑54 13 5 (38.46%) 3 2
55‑59 20 2 (10.00%) 0 2
60‑64 35 7 (20.00%) 5 2
65‑69 42 14 (33.33%) 7 7
70‑74 72 19 (26.38%) 9 10
75‑79 36 14 (38.89%) 11 3
80‑84 26 9 (44.62%) 6 3
85‑89 12 6 (50.00%) 4 2
90‑94 1 1 (100.00%) 1 0
95‑100 2 1 (50.00%) 1 0
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and pulmonary hypertension are known to increase with age.[13] 
Pulmonary hypertension frequency increased progressively 
with age in our study, and the highest frequency of 67% was 
noted in individuals aged 90 years and above [Table 2]. This 
is also in keeping with the findings of Magne et al.[12]
On analysis for gender differences in affectation, pulmonary 
hypertension was significantly more prevalent in males than 
females [Table 2]. Related studies done elsewhere in the past 
have also made similar observations, and reported a higher 
prevalence rate in males than females.[12] The reason for this 
may not be readily obvious, but could also be explained by the 
significantly older male population in our study.
Our findings suggest that degenerative mitral valvular heart 
disease is a frequent etiology of pulmonary hypertension. This 
may result from multiple mechanisms such as an increase 
in pulmonary vascular resistance, pulmonary blood flow, or 
pulmonary venous pressure. The chronic rise in pulmonary 
arterial pressure often leads to right ventricular pressure 
overload and subsequent right ventricular failure. When 
present, pulmonary hypertension is a marker of poor outcome 
in valvular heart disease.
Several studies have demonstrated the negative implications of 
pulmonary hypertension on the natural history and perioperative 
outcomes in mitral valve disease.[14-16] Yang et al. demonstrated 
that preoperative pulmonary hypertension (PASP >30 mmHg) 
is associated with significant reduction in postoperative 
left ventricular ejection fraction (LVEF) in patients with 
degenerative MR and normal preoperative LVEF.[14]
Similarly, another large, multicenter, international study also 
demonstrated that pulmonary hypertension in patients with 
MR approximately doubles the risk of heart failure and death 
after diagnosis and that surgery does not completely abolish 
the risk of adverse events once pulmonary hypertension is 
established.[15]
In a large, single-center study, Ghoreishi et al., showed 
that, in patients with degenerative MR and pulmonary 
hypertension (PASP >40 mmHg) undergoing mitral valve 
surgery (98% underwent mitral valve repair), even mildly 
elevated preoperative PASP correlated with increased operative 
mortality, postoperative left ventricular dysfunction, as well 
as long-term mortality.[16]
A major challenge in this study was addressing the confounding 
effects of cardiac co-morbidities. We endeavored to 
exclude echocardiographic data from patients with a 
history of hemoglobinopathies, diabetes mellitus as well as 
echocardiographic records suggestive of concomitant cardiac 
morbidities. However, the limitation resulting from the failure 
to fully account for the contribution of all co-morbidities likely 
to affect pulmonary pressure in this study is acknowledged.
Conclusion
Pulmonary hypertension is common in middle-aged and elderly 
patients with degenerative mitral valve disease presenting 
for echocardiography in South-East Nigeria, and it is more 
common in males than females. Assessment of the presence 
and severity of pulmonary hypertension has an important 
role in the risk stratification and therapeutic management of 
degenerative mitral valve disease.
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